FidoCure^® Veterinary Team Blog

History and Treatment Planning

A 12 year old, neutered male Golden Retriever, underwent a dental prophylaxis procedure performed by his primary care veterinarian in June of 2021. At that time, no suspicious lesions or growths were noted. In October 2021, his family discovered a marble-sized growth in his mouth along the gum line of his left maxilla. The mass was visible from the outside of his mouth, and seemed to cause him irritation. At the time, it was bloody (perhaps from self trauma/stick chewing). Antibiotics were prescribed, but the dog quickly developed worsening clinic signs (nasal discharge, swelling, lethargy). 

With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic hemangiosarcoma.

Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.

After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.

 

It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.

After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.

 

A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.

After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.

After FidoCure^® enabled treatment, Sam exceeded the 5-7  month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.

With combination therapy that included targeted therapy guided by  FidoCure® genomic sequencing, Heidi has survived over a year following her initial diagnosis of mesothelioma and is still going strong.